oligonucleotide TrkA/TrkB inhibitors (Competence Center for Cancer Research)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug Nameoligonucleotide TrkA/TrkB inhibitors (Competence Center for Cancer Research)

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA

Mechanisms of ActionNeurotrophic tyrosine kinase receptor type 2 inhibitorsNerve growth factor receptor Trk-A antagonists

TargetsNerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCompetence Centre for Cancer Research Ltd. (CCCR)

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCompetence Centre for Cancer Research Ltd. (CCCR)

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A